NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of ...

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in ...

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.

ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics.

Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted ...

OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, forming the combined entity ...

RNA-based vaccines, which instruct cells to produce proteins that can prevent or treat disease, show great promise in ...

Shares in the company are trading nearly 54% down compared to pandemic-high prices. Image credit: Shutterstock/ ShU studio.

WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.

Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...